Erowid
 
 
Plants - Drugs Mind - Spirit Freedom - Law Arts - Culture Library  
Erowid References Database
Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. 
“Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction”. 
J Psychopharmacol. 2014 Nov 17;28(11):983-92.
Show Articles by
  • Johnson MW
  • Garcia-Romeu A
  • Cosimano MP
  • Griffiths RR
    • Article IDs
  • Erowid RefID: 8797
  • PubMedID: 25213996
    • Collections
  • Hofmann Collection
  • MDMA Collection
  • All References


    		•
    Abstract
    Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment protocol. Participants were 15 psychiatrically healthy nicotine-dependent smokers (10 males; mean age of 51 years), with a mean of six previous lifetime quit attempts, and smoking a mean of 19 cigarettes per day for a mean of 31 years at intake. Biomarkers assessing smoking status, and self-report measures of smoking behavior demonstrated that 12 of 15 participants (80) showed seven-day point prevalence abstinence at 6-month follow-up. The observed smoking cessation rate substantially exceeds rates commonly reported for other behavioral and/or pharmacological therapies (typically < 35). Although the open-label design does not allow for definitive conclusions regarding the efficacy of psilocybin, these findings suggest psilocybin may be a potentially efficacious adjunct to current smoking cessation treatment models. The present study illustrates a framework for future research on the efficacy and mechanisms of hallucinogen-facilitated treatment of addiction.
    Comments and Responses to this Article
    #
    Status: display
    earth
    Dec 16, 2014 19:28
    Author's Article about Results #
    http://reset.me/story/psychedelics-treating-tobacco-addictions/

    However, at the height of this research in the early 1970s, when more rigorous and larger studies should have been conducted, these clinically promising compounds became highly restricted, federal sources withdrew research funds to study them, and professional research on them became strongly marginalized. This was not primarily a reaction to medical study results, but was rather a reaction to the recreational use of these drugs and associated social movements, and because a very, very few of the hundreds of scientists who had conducted research with these drugs began to promote their wider recreational use. As Rick Strassman, M.D., stated in his 2001 book DMT: The Spirit Molecule (Park Street Press, p. 28), psychedelics “… began as ‘wonder drugs,’ turned into ‘horror drugs,’ then became nothing” to the medical and scientific community.
    Submit Comment
    [ Cite HTML ]